Injectable therapies remain the gold standard for achieving maximum efficacy, though ongoing innovation in oral GLP-1 formulationssuch as MSD and Hansohs $2 billion licensing deal illustrates strong momentum toward non-invasive delivery methods
In light of the high demand for their tirzepatide and semaglutide products, Lilly and Novo have both made billions worth of investments to expand their production capacities
This raises the exciting possibility that GLP-1-targeting drugs might not only curb appetite, but also improve certain aspects of brain health or conversely, cause unexpected psychiatric side effects
Pay attention to your diet, exercise and behavioral patterns before you go on the medication and after
* **Non-Scale Victories:** Improvements in health markers (blood pressure, blood sugar), energy levels, mobility, and how clothes fit are also important indicators of success
Most diabetes medications target a single hormone pathway, but tirzepatides dual-agonist qualities mean that it can often provide more significant improvements in blood glucose levels and body weight